Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from DT Cloud Star Acquisition Corporation ( (DTSQ) ).
On February 4, 2026, PrimeGen US and DT Cloud Star Acquisition Corporation announced a definitive business combination agreement, signed on February 2, 2026, under which the pioneering stem cell therapy developer will merge with the Nasdaq-listed special purpose acquisition company at an implied equity value of about $1.5 billion. The deal, expected to close in the second half of 2026 subject to shareholder, regulatory and customary closing conditions, is intended to bring PrimeGen US to the public markets under a new Nasdaq ticker and bolster its access to capital to support clinical development, regulatory activities and potential commercialization of its Triple Activated MSC platform for acute liver failure and other regenerative medicine indications, underscoring expectations of large unmet market opportunities but still dependent on future regulatory and clinical outcomes.
More about DT Cloud Star Acquisition Corporation
PrimeGen US, Inc. is a regenerative medicine and biotech company focused on developing innovative stem cell and exosome therapies, leveraging nearly two decades of proprietary stem cell research. Its lead platform centers on Triple Activated Mesenchymal Stem Cells as a novel cell-based treatment for acute liver injury and related critical conditions, including Acute Alcoholic Hepatitis (Acute Liver Failure), with recent milestones such as a Pre-IND meeting with the U.S. Food and Drug Administration on December 17, 2025.
Average Trading Volume: 4,515
Technical Sentiment Signal: Strong Buy
Current Market Cap: $97.73M
For a thorough assessment of DTSQ stock, go to TipRanks’ Stock Analysis page.